

including FTCA coverage; and free clinics that seek to sponsor individuals for deemed PHS employee status for purposes of eligibility for liability protections, including FTCA coverage.

Burden Statement: Burden in this context means the time expended by persons to generate, maintain, retain, disclose, or provide the information

requested. This includes the time needed to review instructions; to develop, acquire, install, and utilize technology and systems for the purpose of collecting, validating and verifying information, processing and maintaining information, and disclosing and providing information; to train personnel and to be able to respond to

a collection of information; to search data sources; to complete and review the collection of information; and to transmit or otherwise disclose the information. The total annual burden hours estimated for this ICR are summarized in the table below.

Total Estimated Annualized Burden Hours:

Form name	Number of respondents	Number of responses per respondent	Total responses	Average burden per response (in hours)	Total burden hours
Application for Health Center Program Recipients for Deemed PHS Employment with Liability Protections Under the FTCA	1,160	1	1,160	2.5	2,900
Application for Deemed Health Center Program Recipients to Sponsor Volunteer Health Professionals for Deemed PHS Employment with Liability Protections Under the FTCA	1,156	3	3,468	2.0	6,936
Volunteer Health Professionals Emergency Deeming Sponsorship Application	60	1	60	1.0	60
Application for Free Clinics to Sponsor Individuals for Deemed PHS Employment with Liability Protections Under the FTCA	374	3	1,122	2.0	2,244
Total	2,750	5,810	12,140

Maria G. Button,
 Director, Executive Secretariat.
 [FR Doc. 2024-06687 Filed 3-28-24; 8:45 am]
 BILLING CODE 4165-15-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Indian Health Service

Change in Publication Policy of Notices of Funding Opportunity

Per the current policy of the Department of Health and Human Services, the Indian Health Service (IHS) will begin using *Grants.gov* as the primary publication outlet for IHS Notices of Funding Opportunity (NOFO), as of February 1, 2024. Links to the announcement in *Grants.gov* and to the NOFO will be posted to the IHS Division of Grants Management website, at <https://www.ihs.gov/dgm/funding/>.

Any questions regarding this change should be directed to the Division of Grants Management by email to *DGM@ihs.gov*.

Roselyn Tso,
 Director, Indian Health Service.
 [FR Doc. 2024-06679 Filed 3-28-24; 8:45 am]
 BILLING CODE 4166-14-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of Closed Meeting

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The purpose of this meeting is to evaluate requests for preclinical development resources for potential new therapeutics for the treatment of cancer. The outcome of the evaluation will provide information to internal NCI committees that will decide whether NCI should support requests and make available contract resources for development of the potential therapeutic to improve the treatment of various forms of cancer. The research proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the proposed research projects, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Cancer Institute Special Emphasis Panel; FEB2024 Cycle 46 NExT SEP Committee Meeting.
Date: May 7, 2024.
Time: 10:00 a.m. to 3:00 p.m.
Agenda: To evaluate the NCI Experimental Therapeutics Program Portfolio.
Place: National Institutes of Health, 9000 Rockville Pike, Building 31, Room 3A44, Bethesda, Maryland 20892 (Virtual Meeting).
Contact Persons: Barbara Mroczkowski, Ph.D., Executive Secretary, Discovery Experimental Therapeutics Program, National Cancer Institute, NIH, 31 Center Drive, Room 3A44, Bethesda, Maryland 20817, 301-496-4291, *mroczkoskib@mail.nih.gov*.
 Toby Hecht, Ph.D., Executive Secretary, Development Experimental Therapeutics Program, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 3W110, Rockville, Maryland 20850, 240-276-5683, *toby.hecht2@nih.gov*.
 (Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

Dated: March 26, 2024.
Melanie J. Pantoja,
 Program Analyst, Office of Federal Advisory Committee Policy.
 [FR Doc. 2024-06744 Filed 3-28-24; 8:45 am]
 BILLING CODE 4140-01-P